Bortezomib-based Regimens Improve Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study
The management experience for plasma cell leukemia (PCL) is still limited by its rare incidence and aggressive course. The goal of this study was to further consolidate the efficacy of bortezomib contained regimens for PCL in Chinese patients. In this study, 56 consecutive PCL patients (14 primary PCL and 42 secondary PCL) were retrospectively enrolled and 42/56 patients received bortezomib-based regimens (including 10/14 pPCL and 32/42 sPCL). Survival data, clinical information and safety about patients were collected and analyzed. In pPCL and sPCL patients, the overall survival rate (ORR) in bortezomib group was 90.0% and 25.0%. The median PFS (progression-free survival) from PCL diagnosis for pPCL and sPCL was 8.3 months vs. 2.9 months(p=0.043) and median overall survival (OS) from PCL diagnosis was 23.3 months vs. 4.0 months. The OS for patients received bortezomib-based regimens (BBR) was significantly longer in both pPCL (8.3 vs. 1.2 months, p=0.002) and sPCL ones (4.3 vs. 1.1 months, P<0.001). In multivariate COX analysis, BBR treatment (p=0.008, HR:0.38; 95% CI: 0.19-0.77) and response ≥VGPR (p=0.035, HR:0.19; 95% CI: 0.04-0.74) were independent predictors of OS for sPCL patients. While for pPCL patients, BBR predicted OS(p=0.029, HR: 0.056, 95%CI: 0.004-0.745) instead of response ≥VGPR (p=0.272, HR:3.365; 95% CI: 0.38-29.303). In conclusion, bortezomib-based regimens could significantly improve OS for both pPCL and sPCL patients.